BiondVax to Present Universal Flu Vaccine Data at Two Upcoming BioPharma Industry Conferences

June 14, 2010 - PRLog -- Press Release   
   
BiondVax to Present Universal Flu Vaccine Data at Two Upcoming BioPharma Industry Conferences

Ness Ziona, Israel – 14 June 2010 – BiondVax Pharmaceuticals Ltd. (TASE: BNDX), an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a Universal Influenza Vaccine, today announced that the company's Chief Scientific Officer, Dr. Tamar Ben Yedidia, will provide an overview of the Company's technology and clinical development progress at two upcoming biopharma industry conferences:

ILSI-Biomed 2010 Conference
14 – 16 June 2010
Tel-Aviv, Israel
Presentation: 15 June 2010, 11:20a.m. – 1:20 p.m. IST
Title: Towards the Development of a Universal Influenza Vaccine

Barcelona Vaccine Forum 2010
21 – 23 June 2010
Barcelona, Spain
Presentation: 21 June 2010, 3:05 p.m. CET
Title: Towards the Development of a Universal Influenza Vaccine

Dr. Tamar Ben-Yedidia has more than 15 years of experience in the field of Immunology, with specific expertise in the development of vaccines.  She started her career with Biotechnology General Ltd, BTG (Rehovot), working on the development of a recombinant Hepatitis-B vaccine.  She joined the Weizmann Institute of Science in 1994, and under the auspices of Prof. Ruth Arnon in the Department of Immunology, worked on the design of a peptide-based vaccine against several pathogens and focused on influenza.  She continued this work when she left the Weizmann Institute in 2004 to join BiondVax.

Dr. Ben Yedidia is often invited to address conferences around the world and is widely published, with numerous refereed articles and invited reviews in various renowned scientific journals.

Dr. Ben Yedidia received her Ph.D. from the Weizmann Institute after completion of her doctoral thesis entitled “A Peptide-Based Vaccine Against Influenza”.

Please see some of Dr. Ben Yedidia’s other articles:
http://www.biondvax.com/128084/Scientific-Publications-1


For further information, please contact:   
Danny Aronovic
Public Relations Consultant
Gelbart-Kahana   Tel: +972-9-899 5813
Mob: +972-50-799 1121
danny@gksmarketing.com

   
About BiondVax Pharmaceuticals Ltd.   
BiondVax Pharmaceuticals (“the Company”), a publicly-traded company (TASE: BNDX) based in Rechovot, Israel, is developing a proprietary, innovative Universal Influenza (“flu”) Vaccine, the Multimeric-001 vaccine, with the potential to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal influenza strains as well as pandemic influenza strains, such as Swine flu and Avian flu.

BiondVax’s proprietary technology utilizes a unique, proprietary combination of conserved epitopes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect.

BiondVax has recently successfully concluded a second Phase I/II clinical trial for its lead product, the Multimeric-001 vaccine.  The vaccine has been shown to be safe and immunogenic in both Phase I/II clinical trials.
For further information on BiondVax, please visit the Company’s website: www.biondvax.com

# # #

BiondVax Pharmaceuticals, a publicly-traded company (TASE: BNDK) based in Rehovot, Israel, is developing a proprietary, innovative Universal Influenza (“flu”) Vaccine with the potential to provide protection against most human influenza virus strains.